Steven M. Grauer

Phosphodiesterase 10A Inhibitor Activity in Preclinical Models of the Positive, Cognitive, and Negative Symptoms of Schizophrenia

Steven M. Grauer, Virginia Pulito, Rachel L. Navarra et al. · Journal of Pharmacology and Experimental Therapeutics · 2009 · 265 citations

WAY-163909 [(7 bR,10 aR)-1,2,3,4,8,9,10,10 a-Octahydro-7 bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole]: A Novel 5-Hydroxytryptamine 2C Receptor-Selective Agonist with Preclinical Antipsychotic-Like Activity

Karen L. Marquis, Annmarie L. Sabb, Sheree F. Logue et al. · Journal of Pharmacology and Experimental Therapeutics · 2006 · 145 citations

Receptor and behavioral pharmacology of WAY-267464, a non-peptide oxytocin receptor agonist

Robert H. Ring, Lee E. Schechter, Sarah K. Leonard et al. · Neuropharmacology · 2009 · 145 citations

Molecular Pharmacology, Behavioral Neuroscience, Medicine +11

Procognitive and Neuroprotective Activity of a Novel α7 Nicotinic Acetylcholine Receptor Agonist for Treatment of Neurodegenerative and Cognitive Disorders

Renza Roncarati, Carla Scali, Thomas A. Comery et al. · Journal of Pharmacology and Experimental Therapeutics · 2009 · 99 citations

The orphan GPCR, GPR88, modulates function of the striatal dopamine system: A possible therapeutic target for psychiatric disorders?

Sheree F. Logue, Steven M. Grauer, Janet Paulsen et al. · Molecular and Cellular Neuroscience · 2009 · 94 citations

Neuropsychology, Psychoactive Drug, Psychiatry +14